Bristol Myers Squibb has reported some new analysis for its investigational cardiovascular drug mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
The new analysis of data from the phase 3 EXPLORER-HCM study found a greater change in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) at week 30 in mavacamten patients compared to placebo.
The 23-item KCCQ quantifies symptoms, physical function social function and quality of life for patients with cardiomyopathy.
“By using this tool, we were able to demonstrate substantial clinical benefits for patients taking mavacamten in the trial, which diminished when patients ended treatment,” commented John Spertus, lead study investigator.
In addition, more patients treated with mavacemten achieved a very large, clinically meaningful improvement in the KCCQ OSS compared to placebo – 35% versus 15%.
He added: “This new analysis of the EXPLORER-HCM data provides important insights into the benefits myosin inhibition can have in improving the health status of patients with severe obstructive hypertrophic cardiomyopathy, a chronic, often debilitating condition.”
http://www.pmlive.com/pharma_news/bms_builds_case_for_cardiovascular_drug_mavacamten_with_new_analysis_1370130